Creative Planning Acquires Kistler-Tiffany Advisors

1 Mins read

Creative Planning, a leading registered investment advisory firm, has recently acquired Kistler-Tiffany Advisors, a renowned financial planning service provider with over $1.3 billion in assets under management.

Expanding Expertise and Resources

With its headquarters in Berwyn, Pa., Kistler-Tiffany Advisors has been delivering top-notch fee-based financial planning services for nearly half a century. The partnership with Creative Planning will allow the firm to scale its operations and enhance its services.

Mike Conner, managing partner at Kistler-Tiffany, expressed his excitement about the deal, recognizing the significant potential that comes with combining their specialized expertise with Creative Planning’s extensive resources. He believes that this collaboration will enable them to deliver unparalleled value to both existing and future clients.

Leveraging Specialized Expertise

Peter Mallouk, CEO of Creative Planning, emphasized the wealth management, estate planning, and business succession expertise of Kistler-Tiffany Advisors as a key factor in pursuing this acquisition. The deal will further strengthen Creative Planning’s position in these areas.

The terms of the acquisition were not disclosed by the company.

Rapid Growth and Success

Known for its rapid growth, Creative Planning has established itself as one of the fastest-growing RIAs in the nation. It had recently acquired the former United Capital business from Goldman Sachs, solidifying its growth trajectory.

Based in Overland Park, Kansas, Creative Planning currently manages and advises over $245 billion in combined assets as of July 1, 2023. The company was ranked No. 3 in the 2023 Top 100 RIA Firms.

Related posts

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Gold Prices Retreat from Record Highs

1 Mins read
Gold prices took a step back from their recent record highs on Monday, as traders paused following a significant rally. The price…

Leave a Reply

Your email address will not be published. Required fields are marked *

9 + 1 =